PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging

INTRODUCTION: Dual antiplatelet therapy and high-intensity statins are the mainstay treatment in patients with acute stage, symptomatic intracranial atherosclerotic stenosis (ICAS). Alirocumab is a monoclonal antibody that can inhibit proprotein convertase subtilisin–kexin type 9 and effectively low...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yen-Chu, Chang, Chia-Hao, Tsai, Yuan-Hsiung, Weng, Hsu-Huei, Lin, Leng-Chieh, Lee, Jiann-Der
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058777/
https://www.ncbi.nlm.nih.gov/pubmed/35487727
http://dx.doi.org/10.1136/bmjopen-2021-060068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058777/
https://www.ncbi.nlm.nih.gov/pubmed/35487727
http://dx.doi.org/10.1136/bmjopen-2021-060068

Ejemplares similares